Van Lanschot Kempen Investment Management N.V. Sells 29,177 Shares of Encompass Health Co. (NYSE:EHC)

Van Lanschot Kempen Investment Management N.V. trimmed its stake in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 551,424 shares of the company's stock after selling 29,177 shares during the period. Van Lanschot Kempen Investment Management N.V. owned about 0.55% of Encompass Health worth $50,924,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EHC. Norges Bank acquired a new position in Encompass Health during the fourth quarter valued at approximately $100,637,000. Raymond James Financial Inc. bought a new position in shares of Encompass Health in the fourth quarter valued at $77,944,000. Jennison Associates LLC acquired a new position in Encompass Health during the fourth quarter worth $52,094,000. abrdn plc bought a new stake in Encompass Health during the fourth quarter worth $17,846,000. Finally, Invesco Ltd. grew its position in shares of Encompass Health by 3.3% in the 4th quarter. Invesco Ltd. now owns 5,536,251 shares of the company's stock valued at $511,273,000 after acquiring an additional 176,135 shares during the period. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Stock Performance

Encompass Health stock traded up $11.92 during trading on Friday, reaching $113.33. The company had a trading volume of 2,076,448 shares, compared to its average volume of 793,072. The firm's 50-day simple moving average is $99.86 and its 200 day simple moving average is $98.37. Encompass Health Co. has a 52 week low of $82.09 and a 52 week high of $114.38. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $11.41 billion, a price-to-earnings ratio of 25.41, a price-to-earnings-growth ratio of 2.31 and a beta of 0.87.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Sell-side analysts forecast that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st were issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.60%. The ex-dividend date was Tuesday, April 1st. Encompass Health's dividend payout ratio is currently 15.25%.

Insider Buying and Selling at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of Encompass Health stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the sale, the chief accounting officer now owns 69,164 shares of the company's stock, valued at approximately $6,798,129.56. This trade represents a 6.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.10% of the company's stock.

Wall Street Analyst Weigh In

EHC has been the subject of several research analyst reports. StockNews.com downgraded shares of Encompass Health from a "buy" rating to a "hold" rating in a report on Wednesday, April 16th. Royal Bank of Canada reiterated an "outperform" rating and set a $110.00 target price on shares of Encompass Health in a research report on Tuesday, February 11th. KeyCorp increased their price objective on shares of Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a research report on Friday. William Blair restated an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. Finally, Barclays raised their price target on shares of Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $109.11.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.